Notably, treatment with Cabozantinib significantly decreased average tumor volume in mice implanted with shNC BT474 cells (p =0.0143), but no significant difference in mice implanted with RNF114 knockdown cells (p = 0.4869) (Figure 9A-C). This evidence concerns the gene RNF114 and neoplasm.